The latest price target for GT Biopharma (NASDAQ:GTBP) was reported by Roth MKM on December 2, 2024. The analyst firm set a price target for $11.00 expecting GTBP to rise to within 12 months (a possible 478.95% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for GT Biopharma (NASDAQ:GTBP) was provided by Roth MKM, and GT Biopharma initiated their buy rating.

There is no last upgrade for GT Biopharma

There is no last downgrade for GT Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on December 2, 2024 so you should expect the next rating to be made available sometime around December 2, 2025.

While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a initiated with a price target of $0.00 to $11.00. The current price GT Biopharma (GTBP) is trading at is $1.90, which is within the analyst’s predicted range.